Spoken Alpha
Bausch & Lomb Corp
Bausch & Lomb manufactures and sells eye health products across three segments: Vision Care (contact lenses and consumer eye care products like lubricating drops and vitamin supplements), Pharmaceuticals (prescription eye medications for conditions including dry eye and glaucoma), and Surgical (intraocular lenses, cataract surgery equipment, and related instruments).
Bausch & Lomb Corp is a Healthcare company operating in Medical Instruments & Supplies with a $6.13B market cap.
Most recent reported earnings: Q3 FY2026 (Nov 3, 2026).
18 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Disclosures
Extracted from Unknown source, 2026-08-30.
Transcripts
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
History
Executives who appear on this company's earnings calls in our corpus, with role and tenure sourced from SEC filings. Click any name for the full role timeline and call appearance history. Per-executive behavioral deviation metrics are available to research subscribers.
Peers
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for BLCO.
$ curl https://api.spokenalpha.com/v1/companies/BLCOFAQ
Spoken Alpha indexes BLCO's earnings call transcripts at https://spokenalpha.com/companies/BLCO. Each call links to attributed speakers and parsed analyst Q&A. Bausch & Lomb Corp's own investor relations page is at https://ir.bausch.com/.
Bausch & Lomb Corp (BLCO) held its most recent earnings call on 2026-07-29, covering fiscal Q2 2026.
Bausch & Lomb Corp (BLCO) operates in the Healthcare sector (Medical Instruments & Supplies industry).
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q3 FY2026 | 2026-11-03 | — | $0.21 | — | — | — | — | EODHD |
| Q2 FY2026 | 2026-07-28 | $0.16 | $0.16 | 0.0% | $1.39B | — | — | EODHD |
| Q1 FY2026 | 2026-04-28 | $0.08 | $0.05 | +60.0% | $1.24B | — | — | EODHD |
| Q4 FY2025 | 2026-02-17 | $0.32 | $0.35 | -8.6% | $1.41B | — | — | EODHD |
| Q3 FY2025 | 2025-10-28 | $0.18 | $0.16 | +12.5% | $1.28B | — | — | EODHD |
| Q2 FY2025 | 2025-07-29 | $0.07 | $0.08 | -12.5% | $1.28B | — | — | EODHD |
| Q1 FY2025 | 2025-04-29 | $-0.07 | $0.02 | -100.0% | $1.14B | — | — | EODHD |
| Q4 FY2024 | 2025-02-18 | $0.25 | $0.24 | +4.2% | $1.28B | — | — | EODHD |
| Q3 FY2024 | 2024-10-29 | $0.17 | $0.16 | +6.3% | $1.20B | — | — | EODHD |
| Q2 FY2024 | 2024-07-30 | $0.13 | $0.12 | +8.3% | $1.22B | — | — | EODHD |
| Q1 FY2024 | 2024-04-30 | $0.07 | $0.07 | 0.0% | $1.10B | — | — | EODHD |
| Q4 FY2023 | 2024-02-20 | $0.24 | $0.17 | +41.2% | $1.17B | — | — | EODHD |
| Q3 FY2023 | 2023-10-31 | $0.22 | $0.19 | +15.8% | $1.01B | — | — | EODHD |
| Q2 FY2023 | 2023-08-01 | $0.18 | $0.15 | +20.0% | $1.03B | — | — | EODHD |
| Q1 FY2023 | 2023-05-02 | $0.10 | $0.14 | -28.6% | $931.0M | — | — | EODHD |
| Q4 FY2022 | 2023-02-21 | $0.23 | $0.22 | +4.5% | $996.0M | — | — | EODHD |
| Q3 FY2022 | 2022-11-01 | $0.31 | $0.23 | +34.8% | $942.0M | — | — | EODHD |
| Q2 FY2022 | 2022-08-03 | $0.29 | $0.20 | +45.0% | $941.0M | — | — | EODHD |
| Q1 FY2022 | 2022-05-16 | $0.15 | $0.23 | -35.9% | $889.0M | — | — | EODHD |
| Q4 FY2021 | 2022-01-12 | $0.55 | $0.33 | +66.7% | $1.00B | — | — | EODHD |
Source: EODHD. BLCO reported actuals as published; sparse fields render as —.